Who are Ganirelix 0.25 mg.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Half-Dose Depot Triptorelin, Dual Trigger, cetrorelix (cetrotide), Antagonist GnRH Cetrotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ganirelix-0-25-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ganirelix 0.25 mg. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ganirelix 0.25 mg. (Ganirelix 0.25 mg.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist. Area: Reproductive Medicine / Fertility.

phase 3 GnRH antagonist GnRH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Ganirelix 0.25 mg. (Ganirelix 0.25 mg.) — Instituto de Investigacion Sanitaria La Fe. Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion to prevent premature ovulation during assisted reproductive procedures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ganirelix 0.25 mg. TARGET	Ganirelix 0.25 mg.	Instituto de Investigacion Sanitaria La Fe	phase 3	GnRH antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor
Dual Trigger	Dual Trigger	Weill Medical College of Cornell University	marketed	Reproductive hormone protocol	GnRH receptor and LH receptor
cetrorelix (cetrotide)	cetrorelix (cetrotide)	Eugonia	marketed	GnRH antagonist	GnRH receptor
Antagonist GnRH Cetrotide	Antagonist GnRH Cetrotide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH antagonist class)

Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
AEterna Zentaris · 2 drugs in this class
El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
Eugonia · 1 drug in this class
Instituto de Investigacion Sanitaria La Fe · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Rabin Medical Center · 1 drug in this class
Sumitomo Pharma Switzerland GmbH · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ganirelix 0.25 mg. — Competitive Intelligence Brief. https://druglandscape.com/ci/ganirelix-0-25-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab